EMS-CHEMIE (EMSN) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
22 Oct, 2026Executive summary
Net sales increased 1.2% YoY to CHF 1,509 million in Jan-Sep 2026; local-currency growth was 4.2%.
Innovation-led growth in high-margin specialties supported significantly higher profitability despite a challenging market environment.
Financial highlights
Jan-Sep net sales were CHF 1,509 million, up from CHF 1,491 million YoY; reported growth was 1.2%.
Higher raw material costs were offset through corresponding sales price adjustments.
Outlook and guidance
FY 2026 net sales are now expected at the prior-year level; EBIT remains expected slightly above the prior year.
Q4 is expected to remain challenging, with inflation, high fuel prices, weak domestic Chinese demand and a strong Swiss franc weighing on conditions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from EMS-CHEMIE
- FY2023 earnings weakened, while FY2024 guidance anticipates stable sales and higher EBIT.EMSN
H2 2023 - EBIT margin rose to 30.6% and a CHF 18.40 per share dividend was approved.EMSNQ2 2026
- EBIT and volumes up, but net sales down 6.6% year-over-year due to currency headwinds.EMSNQ1 2026
- EBIT rose 5.2% to CHF 567 million, with improved margins and strong cash flow in 2025.EMSNQ4 2025
- Net sales fell 6.2% but profitability rose, with EBIT expected slightly above last year.EMSNQ3 2025
- EBIT and margins rose despite lower sales, supported by innovation and high-margin specialties.EMSNQ2 2025
- Net sales declined but EBIT improved, driven by new business and segment expansion.EMSNQ3 2024
- EBIT and net income rose despite lower sales, with improved margins and strong equity ratio.EMSNH1 2024
- Q1 2025 sales fell 4.3%, but innovation and new business kept EMS Group's EBIT outlook positive.EMSNQ1 2025